Biomolecules to Biomarkers? U87MG Marker Evaluation on the Path towards Glioblastoma Multiforme Pathogenesis

Markéta Pokorná,Viera Kútna,Saak V. Ovsepian,Radoslav Matěj,Marie Černá,Valerie Bríd O'Leary
DOI: https://doi.org/10.3390/pharmaceutics16010123
IF: 6.525
2024-01-18
Pharmaceutics
Abstract:The heterogeneity of the glioma subtype glioblastoma multiforme (GBM) challenges effective neuropathological treatment. The reliance on in vitro studies and xenografted animal models to simulate human GBM has proven ineffective. Currently, a dearth of knowledge exists regarding the applicability of cell line biomolecules to the realm of GBM pathogenesis. Our study's objectives were to address this preclinical issue and assess prominin-1, ICAM-1, PARTICLE and GAS5 as potential GBM diagnostic targets. The methodologies included haemoxylin and eosin staining, immunofluorescence, in situ hybridization and quantitative PCR. The findings identified that morphology correlates with malignancy in GBM patient pathology. Immunofluorescence confocal microscopy revealed prominin-1 in pseudo-palisades adjacent to necrotic foci in both animal and human GBM. Evidence is presented for an ICAM-1 association with degenerating vasculature. Significantly elevated nuclear PARTICLE expression from in situ hybridization and quantitative PCR reflected its role as a tumor activator. GAS5 identified within necrotic GBM validated this potential prognostic biomolecule with extended survival. Here we present evidence for the stem cell marker prominin-1 and the chemotherapeutic target ICAM-1 in a glioma animal model and GBM pathology sections from patients that elicited alternative responses to adjuvant chemotherapy. This foremost study introduces the long non-coding RNA PARTICLE into the context of human GBM pathogenesis while substantiating the role of GAS5 as a tumor suppressor. The validation of GBM biomarkers from cellular models contributes to the advancement towards superior detection, therapeutic responders and the ultimate attainment of promising prognoses for this currently incurable brain cancer.
pharmacology & pharmacy
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate and verify the potential of certain biomolecules (such as prominin - 1, ICAM - 1, PARTICLE and GAS5) as diagnostic markers for glioblastoma multiforme (GBM). Specifically, the research aims to: 1. **Evaluate the applicability of biomolecules as GBM diagnostic markers**: By obtaining data in the U87MG cell line in vitro and comparing it with data in rodent and human GBM pathological specimens, to verify the expression of these biomolecules in GBM and their potential diagnostic value. 2. **Explore the role of these biomolecules in the GBM pathological process**: In particular, study the expression patterns of these biomolecules in pathological sections of GBM patients and their relationship with the tumor microenvironment, such as pseudo - palisades and necrotic foci. 3. **Analyze the differences in biomolecule expression in patients with different treatment responses**: By analyzing GBM patients who are responsive and non - responsive to temozolomide chemotherapy, explore whether these biomolecules can be used as markers for predicting treatment response. ### Main research objects and methods - **Research objects**: - **Human GBM patients**: Four GBM patients were selected, some of whom were responsive to temozolomide chemotherapy and some were not. - **Eker rat model**: Eker rats carrying the Tsc2 gene mutation were used as an animal model to simulate human GBM. - **Research methods**: - **Histological staining**: Including hematoxylin - eosin staining (H&E), immunofluorescence, in - situ hybridization and quantitative PCR. - **Immunohistochemistry**: Detect the expression of prominin - 1, ICAM - 1 and GFAP (astrocyte marker). - **Fluorescence in - situ hybridization**: Detect the expression of long - non - coding RNA (lncRNA) PARTICLE and GAS5. - **Real - time quantitative PCR**: Extract RNA from GBM pathological sections to detect the expression levels of PARTICLE and GAS5. ### Main findings 1. **Morphological features are related to the degree of malignancy**: Pathological sections of GBM patients showed that tumor cell clusters were interlaced with necrotic areas, rich in blood vessels, and had significant nuclear atypia, and these features were related to the degree of malignancy. 2. **Expression of prominin - 1 in pseudo - palisades**: In GBM pathological sections of humans and Eker rats, prominin - 1 was mainly expressed in endothelial cells around pseudo - palisades, but did not co - localize with astrocytes. 3. **ICAM - 1 is related to degenerated blood vessels**: ICAM - 1 was widely expressed in GBM pathological sections, especially in small oval - shaped structures, which may represent areas of microvascular hyperplasia. High expression of ICAM - 1 was related to degenerated blood vessels. 4. **Differences in PARTICLE and GAS5 expression**: Through in - situ hybridization and quantitative PCR, it was found that the expression of PARTICLE in GBM was significantly increased, and the expression of GAS5 in necrotic areas verified its potential as a prognostic marker. ### Conclusion This study provides preliminary evidence for evaluating prominin - 1, ICAM - 1, PARTICLE and GAS5 as GBM diagnostic and prognostic markers. The expression patterns of these biomolecules in GBM and their relationship with the tumor microenvironment provide important clues for further research and development of new treatment strategies.